CYTK Stock Analysis: Cytokinetics | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 7.819m USD | 12M Return: -22.4% | US23282W6057 | Charts, Fundamentals & Technical Analysis

Cardiac Myosin Inhibitors, Heart Failure Drugs, Muscle Activators, HCM Treatments
Total Rating 14
Safety 29
Buy Signal -0.44
Biotechnology
Sub-Industry Rotation: +5.4
Market Cap: 7.82B
Avg Turnover: 106M
Risk 3d forecast
Volatility58.3%
VaR 5th Pctl8.61%
VaR vs Median-8.12%
Reward TTM
Sharpe Ratio-0.45
Rel. Str. IBD7.3
Rel. Str. Peer Group15.8 pctl
Character TTM
Beta0.988
Beta Downside0.884
Hurst Exponent0.473
Choppyness17.9%
Drawdowns 3y
Max DD72.39%
CAGR/Max DD0.24
CAGR/Mean DD0.39
EPS (Earnings per Share) EPS (Earnings per Share) of CYTK over the last years for every Quarter: "2021-09": -0.95, "2021-12": -0.36, "2022-03": -1.02, "2022-06": -0.23, "2022-09": -1.28, "2022-12": -1.45, "2023-03": -1.38, "2023-06": -1.34, "2023-09": -1.35, "2023-12": -1.38, "2024-03": -1.33, "2024-06": -1.31, "2024-09": -1.36, "2024-12": -1.26, "2025-03": -1.36, "2025-06": -1.12, "2025-09": -1.54, "2025-12": -1.5, "2026-03": -1.67, "2026-06": -1.5, "2026-09": -1.37,
Last SUE: 1.17
Qual. Beats: 1
Revenue Revenue of CYTK over the last years for every Quarter: 2021-09: 5.437, 2021-12: 55.6, 2022-03: 1.148, 2022-06: 88.968, 2022-09: 2.515, 2022-12: 1.957, 2023-03: 4.613, 2023-06: 0.867, 2023-09: 0.378, 2023-12: 1.672, 2024-03: 0.835, 2024-06: 0.249, 2024-09: 0.463, 2024-12: 16.927, 2025-03: 1.579, 2025-06: 66.769, 2025-09: 1.936, 2025-12: 17.755, 2026-03: 19.355, 2026-06: 28.624, 2026-09: 47.557,
Rev. CAGR: 323.39%
Rev. Trend: 88.6%
Last SUE: 0.23
Qual. Beats: 0

Warnings

Negative Equity With Losses
Strong Share Dilution
Interest Coverage Ratio Critical
Beneish M-Score Likely Earnings Manipulation
Altman Z'' In Financial Distress Zone
Favorite
Below Avwap Earnings
Below Sma 200d

Tailwinds

Confidence

Seasonality 11.9 years of data, until 10/2026

Jan -3.1% 9
Feb -3.2% 28
Mar -0.2% 0
Apr +3.0% 28
May -1.3% 4
Jun +0.2% 0
Jul +3.1% 4
Aug +3.8% 47
Sep -3.7% 14
Oct -1.8% 28
Nov +5.0% 21
Dec -1.6% 9

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: CYTK Cytokinetics

Cytokinetics, Incorporated (NASDAQ: CYTK) is a U.S.-based biopharmaceutical company founded in 1997 and headquartered in South San Francisco, California. The company specializes in discovering, developing, and commercializing novel small molecule therapeutics that target muscle contractility, including both muscle activators and inhibitors, aimed at treating debilitating diseases.

The companys commercial product, MYQORZO, is an oral cardiac myosin inhibitor approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Its pipeline includes Aficamten, a cardiac myosin inhibitor in development for hypertrophic cardiomyopathy, and omecamtiv mecarbil, a potential treatment for heart failure with severely reduced ejection fraction. Earlier-stage candidates include Ulacamten (Phase 1) for heart failure with preserved ejection fraction and CK-089 (Phase 1), a fast skeletal muscle troponin activator.

As a mid-cap biotechnology company, Cytokinetics operates within a sector characterized by lengthy and capital-intensive drug development cycles, reliance on intellectual property protection, and revenue heavily dependent on regulatory approvals and successful commercialization. The company went public in 2004 and primarily generates income through product sales supplemented by collaboration and licensing arrangements common across the biopharmaceutical industry.

Headlines to Watch Out For
  • MYQORZO launch revenue accelerates in oHCM market
  • Aficamten Phase 3 data drives regulatory submission timeline
  • Omecamtiv mecarbil approval expands heart failure treatment portfolio
Piotroski VR-10 (Strict) 1.5
Net Income: -777.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.36 > 0.02 and ΔFCF/TA 9.97 > 1.0
NWC/Revenue: 735.9% < 20% (prev 957.7%; Δ -221.8% < -1%)
CFO/TA -0.31 > 3% & CFO -572.0m > Net Income -777.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.36 > 1.5 & < 3
Outstanding Shares: last quarter (139.0m) vs 12m ago 15.89% < -2%
Gross Margin: 91.00% > 18% (prev -127.5%; Δ 218.5% > 0.5%)
Asset Turnover: 6.95% > 50% (prev 6.07%; Δ 0.88% > 0%)
Interest Coverage Ratio: -5.15 > 6 (EBIT TTM -706.1m / Interest Expense TTM 137.0m)
Altman Z'' -7.36
A: 0.46 (Total Current Assets 1.19b - Total Current Liabilities 353.4m) / Total Assets 1.82b
B: -2.24 (Retained Earnings -4.08b / Total Assets 1.82b)
C: -0.43 (EBIT TTM -706.1m / Avg Total Assets 1.63b)
D: -0.15 (Book Value of Equity -321.2m / Total Liabilities 2.15b)
Altman-Z'' = -7.36 = D
Beneish M -1.02
DSRI: 3.0 (Receivables 33.9m/1.81m, Revenue 113.3m/87.2m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.26 (AQ_t 0.27 / AQ_t-1 0.21)
SGI: 1.30 (Revenue 113.3m / 87.2m)
TATA: -0.11 (NI -777.9m - CFO -572.0m) / TA 1.82b)
Beneish M = -1.02 (Cap -4..+1) = D
What is the price of CYTK shares?

As of November 19, 2026, the stock is trading at USD 51.32 with a total of 1,594,452 shares traded. Over the past week, the price has changed by -12.32%, over one month by -18.08%, over three months by -32.56% and over the past year by -22.43%.

Current recommended Stop Loss: 48.20 (which is 6.1% or 1.2 ATR below the current price).

Is CYTK a buy, sell or hold?

Cytokinetics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy CYTK.

  • StrongBuy: 13
  • Buy: 7
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CYTK price?
Analysts Target Price 109.4 113.2%
Cytokinetics (CYTK) - Fundamental Data Overview as of 16 November 2026
Market Cap USD = 7.82b (7.82b USD * 1.0 USD.USD)
P/E Forward = 117.6471
P/S = 69.0178
P/B = 60.3093
P/EG = -0.42
Revenue TTM = 113.3m USD
EBIT TTM = -706.1m USD
EBITDA TTM = -692.6m USD
Long Term Debt = 977.1m USD (from longTermDebt, last quarter)
Short Term Debt = 195.8m USD (from shortTermDebt, last quarter)
Debt = 1.39b USD (from shortLongTermDebtTotal, last quarter) + Leases 121.1m
Net Debt = 442.2m USD (calculated: Debt 1.39b - CCE 951.4m)
Enterprise Value = 8.26b USD (7.82b + Debt 1.39b - CCE 951.4m)
Interest Coverage Ratio = -5.15 (Ebit TTM -706.1m / Interest Expense TTM 137.0m)
EV/FCF = -12.72x (Enterprise Value 8.26b / FCF TTM -649.7m)
FCF Yield = -7.86% (FCF TTM -649.7m / Enterprise Value 8.26b)
 FCF Margin = -573.4% (FCF TTM -649.7m / Revenue TTM 113.3m)
 Net Margin = -686.6% (Net Income TTM -777.9m / Revenue TTM 113.3m)
 Gross Margin = 91.00% ((Revenue TTM 113.3m - Cost of Revenue TTM 10.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev 90.46%)
Tobins Q-Ratio = 4.53 (Enterprise Value 8.26b / Total Assets 1.82b)
Interest Expense / Debt = 9.83% (Interest Expense 137.0m / Debt 1.39b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -557.8m (EBIT -706.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.13 (Total Current Assets 1.19b / Total Current Liabilities 379.4m)
 Debt / Equity = -4.34 (negative equity) (Debt 1.39b / totalStockholderEquity, last quarter -321.2m)
 Debt / EBITDA = -0.64 (negative EBITDA) (Net Debt 442.2m / EBITDA -692.6m)
 Debt / FCF = -0.68 (negative FCF - burning cash) (Net Debt 442.2m / FCF TTM -649.7m)
 Total Stockholder Equity = -495.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.70% (Net Income -777.9m / Total Assets 1.82b)
 RoE = 157.1% (negative equity) (Net Income TTM -777.9m / Total Stockholder Equity -495.2m)
 RoCE = -146.5% (out of range, set to none) (EBIT -706.1m / Capital Employed (Equity -495.2m + L.T.Debt 977.1m))
 RoIC = -33.57% (negative operating profit) (NOPAT -557.8m / Invested Capital 1.66b)
 WACC = 8.78% (E(7.82b)/V(9.21b) * Re(8.96%) + D(1.39b)/V(9.21b) * Rd(9.83%) * (1-Tc(0.21)))
Discount Rate = 8.96% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.52 | Cagr: 11.32%
 [DCF] Fair Price = unknown (Cash Flow -649.7m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.17 | # QB: 1
Revenue Correlation: 88.56 | Revenue CAGR: 323.4% | SUE: 0.23 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-1.28 | Chg30d=+3.88% | Revisions=+50% | Analysts=6
EPS current Year (2026-12-31): EPS=-5.76 | Chg30d=+2.91% | Revisions=+46% | GrowthEPS=+11.9% | GrowthRev=+86.9%
EPS next Year (2027-12-31): EPS=-4.23 | Chg30d=+4.76% | Revisions=+50% | GrowthEPS=+26.6% | GrowthRev=+169.3%
[Analyst] Revisions Ratio: +59% (up=20, down=4)